Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (151-160 of 212) with videos related to

Pageof 22
Sort By:
American Journal of Hematology|February 15, 2016
Autoimmune diseases and myelodysplastic syndromesRami S Komrokji, Austin Kulasekararaj, Najla H Al Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Nature Cell Biology|April 7, 2020
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndromeSergio Martinez-Høyer, Yu Deng, Jeremy Parker, et al.
Blood|May 2, 2013
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemiaEric Padron, Jeffrey S Painter, Sateesh Kunigal, et al.
Leukemia|February 10, 2019
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromesPinyang Cheng, Erika A Eksioglu, Xianghong Chen, et al.
Blood|June 4, 2014
Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDSGanesan Keerthivasan, Yang Mei, Baobing Zhao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2022
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanomaPingyan Cheng, Xianghong Chen, Robert Dalton, et al.
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
Blood|June 7, 2014
ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemiaEric Padron, Sean Yoder, Sateesh Kunigal, et al.
Leukemia Research|March 6, 2012
Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium studySusan Bell Nyland, Daniel J Krissinger, Michael J Clemente, et al.
Pageof 22

Showing results (151-160 of 212) with videos related to

Sort By:
Pageof 22
American Journal of Hematology|February 15, 2016
Autoimmune diseases and myelodysplastic syndromesRami S Komrokji, Austin Kulasekararaj, Najla H Al Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Nature Cell Biology|April 7, 2020
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndromeSergio Martinez-Høyer, Yu Deng, Jeremy Parker, et al.
Blood|May 2, 2013
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemiaEric Padron, Jeffrey S Painter, Sateesh Kunigal, et al.
Leukemia|February 10, 2019
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromesPinyang Cheng, Erika A Eksioglu, Xianghong Chen, et al.
Blood|June 4, 2014
Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDSGanesan Keerthivasan, Yang Mei, Baobing Zhao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2022
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanomaPingyan Cheng, Xianghong Chen, Robert Dalton, et al.
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
Blood|June 7, 2014
ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemiaEric Padron, Sean Yoder, Sateesh Kunigal, et al.
Leukemia Research|March 6, 2012
Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium studySusan Bell Nyland, Daniel J Krissinger, Michael J Clemente, et al.
Pageof 22